Grant: Operating Grant - Priority Announcement: Infection and Immunity (Bridge Funding)
University of British Columbia
$98,674.00
CpG oligonucleotides improve cardiac inflammation and dysfunction through the induction of a suppressive network of anti-inflammatory genes in the heart.
EF 2009-10
Résumé
The Health Problem: A wide array of injuries to the heart result in impaired function, also known as heart failure. It is becoming clear that while the causes of an initial injury to the heart are diverse, the way in which the heart responds to injury is of great importance. The type of response to injury mandates whether the heart heals and regains function, or conversely whether there is an amplification of injury and worsening heart failure. This amplification of injury is termed inflammation.
Objective of the study: I am interested in understanding the common pathways through which the heart responds to injuries, and using therapy aimed at the heart-specific immune system to tilt the response to injury in favour of healing. Specifically I aim to understand how heart muscle cells become inflamed and lose their ability to contract as a result of the two most common diseases I see while working in the intensive care unit, severe infection and heart attacks (also known as myocardial infarction). As a result of ongoing work in this area I have identified a drug currently used in clinical trials to change the immune system and help fight cancer and boost vaccines, called CpG, as being capable of safely decreasing
heart dysfunction resulting from injury and inflammation. The second objective of this project is to learn how and when it is most effective to give CpG when the heart is injured.
Research Plan: This research proposal will use small animal (mouse) models of heart attacks and severe infection to study the heart specific inflammatory response to injury. Specifically, we will study isolated, contracting heart cells to confirm thatproteins made in response to injury do result in cardiac inflammation and reduced contraction. In both the isolated heart cells and in the live mouse we will treat with CpG before, during or after the heart injury and study how and when CpG protects the heart.
Programme
Operating Grant - Priority Announcement: Infection and Immunity (Bridge Funding)
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
208511
Name
Boyd John H
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Clinical
Prcname2
Cardiovascular System - B: Heart and Circulation
Projecttitle
CpG oligonucleotides improve cardiac inflammation and dysfunction through the induction of a suppressive network of anti-inflammatory genes in the heart.
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$98,674
Cihrequipment2
$0
Programname2
Operating Grant - Priority Announcement: Infection and Immunity (Bridge Funding)
Keyworddelim
Cardiac Failure; Cpg Oligonucleotides; Innate Immunity; Ischemic Heart Disease; Sepsis; Toll Like Receptors
Abstract
The Health Problem: A wide array of injuries to the heart result in impaired function, also known as heart failure. It is becoming clear that while the causes of an initial injury to the heart are diverse, the way in which the heart responds to injury is of great importance. The type of response to injury mandates whether the heart heals and regains function, or conversely whether there is an amplification of injury and worsening heart failure. This amplification of injury is termed inflammation.
Objective of the study: I am interested in understanding the common pathways through which the heart responds to injuries, and using therapy aimed at the heart-specific immune system to tilt the response to injury in favour of healing. Specifically I aim to understand how heart muscle cells become inflamed and lose their ability to contract as a result of the two most common diseases I see while working in the intensive care unit, severe infection and heart attacks (also known as myocardial infarction). As a result of ongoing work in this area I have identified a drug currently used in clinical trials to change the immune system and help fight cancer and boost vaccines, called CpG, as being capable of safely decreasing
heart dysfunction resulting from injury and inflammation. The second objective of this project is to learn how and when it is most effective to give CpG when the heart is injured.
Research Plan: This research proposal will use small animal (mouse) models of heart attacks and severe infection to study the heart specific inflammatory response to injury. Specifically, we will study isolated, contracting heart cells to confirm thatproteins made in response to injury do result in cardiac inflammation and reduced contraction. In both the isolated heart cells and in the live mouse we will treat with CpG before, during or after the heart injury and study how and when CpG protects the heart.
Competitiondate
201003
Approvedterm2
1 yr 0 mth
Pinamesdelim
Boyd, John H
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $98,674~ $0~